Daveen  Chopra net worth and biography

Daveen Chopra Biography and Net Worth

Daveen Chopra has been corporate vice president, Surgical Structural Heart since May 2018. Chopra has broad experience in the medical technology industry, including global leadership in strategy, marketing, commercial operations, research and development, and program management. Prior to joining Edwards, Chopra held various roles with increasing levels of responsibility at Medtronic, plc, from 2005 to 2018, culminating in a global leadership role as vice president and general manager of its aortic franchise. Chopra previously served as vice president of global marketing leading Medtronic’s endovascular therapies business. While in Medtronic’s endovascular therapies business, he served as vice president, U.S. commercial operations, director of program management office, senior business manager for the endovascular and peripheral business in Asia-Pacific, global group product manager for thoracic stent grafts, and international aortic product manager. Prior to Medtronic, Chopra served as an international strategy consultant at The Parthenon Group supporting clients in various industries ranging from education to industrial manufacturing. In 2020, he joined the board of the Edwards Lifesciences Foundation, and, in 2021, he joined the board of Octane. Chopra earned a dual bachelor’s degree in economics and biology from Duke University, and a masters from Harvard Business School, where he graduated with honors.

What is Daveen Chopra's net worth?

The estimated net worth of Daveen Chopra is at least $2.05 million as of February 21st, 2024. Mr. Chopra owns 22,750 shares of Edwards Lifesciences stock worth more than $2,048,865 as of April 16th. This net worth estimate does not reflect any other assets that Mr. Chopra may own. Learn More about Daveen Chopra's net worth.

How do I contact Daveen Chopra?

The corporate mailing address for Mr. Chopra and other Edwards Lifesciences executives is ONE EDWARDS WAY, IRVINE CA, 92614. Edwards Lifesciences can also be reached via phone at (949) 250-2500 and via email at [email protected]. Learn More on Daveen Chopra's contact information.

Has Daveen Chopra been buying or selling shares of Edwards Lifesciences?

Daveen Chopra has not been actively trading shares of Edwards Lifesciences during the past quarter. Most recently, Daveen Chopra sold 8,200 shares of the business's stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $86.74, for a transaction totalling $711,268.00. Following the completion of the sale, the vice president now directly owns 22,750 shares of the company's stock, valued at $1,973,335. Learn More on Daveen Chopra's trading history.

Who are Edwards Lifesciences' active insiders?

Edwards Lifesciences' insider roster includes Donald Bobo, Jr (VP), Daveen Chopra (VP), Kieran Gallahue (Director), Leslie Heisz (Director), Jean-Luc Lemercier (VP), Martha Marsh (Director), Michael Mussallem (CEO), Robert Sellers (VP), Catherine Szyman (VP), Scott Ullem (CFO), Nicholas Valeriani (Director), Huimin Wang (VP), Larry Wood (VP), and Bernard Zovighian (VP). Learn More on Edwards Lifesciences' active insiders.

Are insiders buying or selling shares of Edwards Lifesciences?

In the last year, insiders at the medical research company sold shares 60 times. They sold a total of 768,312 shares worth more than $62,771,727.15. The most recent insider tranaction occured on April, 8th when VP Jean-Luc M Lemercier sold 14,400 shares worth more than $1,329,408.00. Insiders at Edwards Lifesciences own 1.3% of the company. Learn More about insider trades at Edwards Lifesciences.

Information on this page was last updated on 4/8/2024.

Daveen Chopra Insider Trading History at Edwards Lifesciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2024Sell8,200$86.74$711,268.0022,750View SEC Filing Icon  
12/15/2023Sell7,000$78.25$547,750.0023,950View SEC Filing Icon  
12/6/2023Sell3,500$70.00$245,000.0023,950View SEC Filing Icon  
10/3/2023Sell8,500$70.00$595,000.0023,950View SEC Filing Icon  
9/6/2023Sell8,500$76.07$646,595.0023,950View SEC Filing Icon  
8/29/2023Sell1,500$76.69$115,035.0023,950View SEC Filing Icon  
3/15/2023Sell4,435$77.47$343,579.4518,911View SEC Filing Icon  
2/15/2023Sell4,000$76.01$304,040.0018,911View SEC Filing Icon  
1/17/2023Sell4,000$78.00$312,000.0018,911View SEC Filing Icon  
12/15/2022Sell4,000$74.80$299,200.0018,911View SEC Filing Icon  
11/15/2022Sell4,000$74.18$296,720.0018,911View SEC Filing Icon  
10/14/2022Sell4,000$84.77$339,080.0018,911View SEC Filing Icon  
8/2/2022Sell1,000$102.49$102,490.0018,911View SEC Filing Icon  
5/26/2022Sell1,000$98.31$98,310.0019,911View SEC Filing Icon  
See Full Table

Daveen Chopra Buying and Selling Activity at Edwards Lifesciences

This chart shows Daveen Chopra's buying and selling at Edwards Lifesciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edwards Lifesciences Company Overview

Edwards Lifesciences logo
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $90.06
Low: $87.87
High: $90.40

50 Day Range

MA: $90.07
Low: $84.87
High: $95.56

2 Week Range

Now: $90.06
Low: $60.57
High: $96.12

Volume

2,640,500 shs

Average Volume

3,888,942 shs

Market Capitalization

$54.21 billion

P/E Ratio

39.16

Dividend Yield

N/A

Beta

1.05